CD33CAR-CD3zeta-4-1BB-expressing Autologous T-Lymphocytes

Known as: Anti-CD33 TCR zeta:CD137 CAR T Cells, CART-33 TCR zeta:CD137 Cells, CART33 TCR zeta:CD137 Cells 
Autologous T-lymphocytes transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD33 scFv (single… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2003-2014
0120032014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
  • Bettina Weigelina, Elixabet Bolañosb, +10 authors Ignacio Melerob
  • 2015
Cancer immunotherapy is undergoing significant progress due to recent clinical successes by refined adoptive T-cell transfer and… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
Immunotherapy is a promising strategy against hepatocellular carcinoma (HCC). We assessed the therapeutic effects of stimulating… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2009
2009
Anti-CD137 mAb are capable of inducing tumor rejection in several syngeneic murine tumor models and are undergoing clinical… (More)
Is this relevant?
2003
2003
Experimental autoimmune thyroiditis (EAT), a model for Hashimoto's thyroiditis, is a T cell-mediated disease inducible with mouse… (More)
Is this relevant?